We now confirm that introduction of FGF1 to drug-sensitive cells confers resistance, and that resistance is reversible by co-administration of pharmacological FGFR inhibitors in both immortalised cell lines and primary ascites-derived cell lines from drug-resistant ovarian cancer patients. Here, FGF1 is linked to ovarian carcinoma.